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BACKGROUND: Babies of women with heterozygous
pathogenic glucokinase (GCK) variants causing mild
fasting hyperglycemia are at risk of macrosomia if
they do not inherit the variant. Conversely, babies
who inherit a pathogenic hepatocyte nuclear factor
4a (HNF4A) diabetes variant are at increased risk of
high birth weight. Noninvasive fetal genotyping for
maternal pathogenic variants would inform pregnancy
management.
METHODS: Droplet digital PCR was used to quantify ref-
erence and variant alleles in cell-free DNA extracted
from blood from 38 pregnant women heterozygous for
a GCK or HNF4A variant and to determine fetal frac-
tion by measurement of informative maternal and pater-
nal variants. Droplet numbers positive for the reference/
alternate allele together with the fetal fraction were used
in a Bayesian analysis to derive probability for the fetal
genotype. The babies’ genotypes were ascertained
postnatally by Sanger sequencing.
RESULTS: Droplet digital PCR assays for GCK or HNF4A
variants were validated for testing in all 38 pregnancies.
Fetal fraction of 2% was demonstrated in at least 1
cell-free DNA sample from 33 pregnancies. A threshold
of 0.95 for calling homozygous reference genotypes
and 0.05 for heterozygous fetal genotypes allowed cor-
rect genotype calls for all 33 pregnancies with no false-
positive results. In 30 of 33 pregnancies, a result was
obtained from a single blood sample.
CONCLUSIONS: This assay can be used to identify
pregnancies at risk of macrosomia due to maternal
monogenic diabetes variants.
Introduction
Prenatal diagnostic testing has been transformed
through the discovery in 1997 of cell-free fetal DNA
(cffDNA) in maternal plasma during pregnancy (1).
Noninvasive prenatal testing (NIPT) of cffDNA is now
widely used to screen for Down syndrome and other
aneuploidies (2), fetal sexing (3), and RhD blood group
genotyping (4). More recently, NIPT has also been used
for monogenic diseases. In the case of paternally inher-
ited or de novo pathogenic variants, determination of
the fetal genotype is relatively straightforward, indicated
by low-level presence of disease-specific alleles in cell-
free DNA (cfDNA) measured either by allele-specific as-
say (5–7) or by clinical exome sequencing (8). NIPT
has also been used in cases of monogenic X-linked or
autosomal recessive disorders, through use of relative
haplotype dosage analysis (9, 10) or droplet digital PCR
(ddPCR) (11).
NIPT for maternally inherited variants that cause
autosomal dominant disorders presents a particular chal-
lenge because only a small proportion of the total
cfDNA in maternal blood is derived from the fetus dur-
ing early pregnancy (12). In such cases, a highly sensi-
tive and precise method is required to quantify the
presence of both reference and variant alleles to distin-
guish between fetal inheritance of the maternal vari-
ant—whereby cfDNA will show a 50:50 allelic ratio
due to both mother and fetus being heterozygous—and
noninheritance, where the normal allele will be overrep-
resented in proportion to the amount of fetal DNA pre-
sent within the sample. For example, a case of
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noninheritance in which 10% of the cfDNA originates
from the fetus would be expected to produce a 55:45 ra-
tio of reference and variant alleles.
An estimated 0.1% of the white population has a
pathogenic or likely pathogenic glucokinase (GCK) vari-
ant causing mild fasting hyperglycemia from birth.
These variants account for approximately 1% of gesta-
tional diabetes (13). Babies of women with (likely) path-
ogenic heterozygous GCK variants are at risk of
macrosomia if they do not inherit the variant.
Conversely, babies who inherit a pathogenic or likely
pathogenic hepatocyte nuclear factor 4a (HNF4A)
monogenic diabetes variant from their mother are at in-
creased risk of high birth weight. Currently, the risk and
management of macrosomia is based on tight maternal
glycemic control and serial ultrasound scans from
26 weeks, with the option of preterm delivery or elective
cesarean or the induction of labor at 38 weeks.
Detection of macrosomia by ultrasound analysis relies
on measurement of fetal metrics (abdominal circumfer-
ence, head circumference, biparietal diameter and femur
length) to derive a proxy for fetal weight by combina-
tion into 1 formula (14). However, this method lacks
reliability, with one study estimating the accuracy as
56%–72% depending on the formula used (15), and by
definition relies on the prior manifestation of fetal over-
growth for diagnosis. As such, a cost–benefit analysis of
macrosomia prediction by ultrasound concluded that its
use to inform elective cesarean was economically unvi-
able in uncomplicated pregnancies (16). In contrast, the
much higher rate of macrosomia encountered in preg-
nancies with maternal diabetes provides a greater incen-
tive to develop more accurate tools for the prediction of
macrosomia risk; in cases of monogenic diabetes, the
prenatal prediction of fetal genotype provides one such
tool. Because termination of pregnancy is not a consid-
eration in cases of monogenic diabetes, a noninvasive
method of testing is highly preferable, as it eliminates
the small but extant risk of miscarriage or other compli-
cations associated with the invasive methods of amnio-
centesis or chorionic villus sampling. We sought to
inform future clinical management for this patient
group by developing a noninvasive genotyping test
based on the highly sensitive and precise method of
ddPCR.
Materials and Methods
PATIENT RECRUITMENT AND ETHICS
Patients with known monogenic forms of diabetes
caused by single-nucleotide variants (SNVs) or 1- or 2-
bp insertions or deletions (indels) in GCK or HNF4A
were recruited during pregnancy. Eligible patients were
identified through the Exeter Genomics Laboratory
monogenic diabetes testing service, Health Education
England (HEE)-funded genetic diabetes nurses, endo-
crinologists, or self-referral. All participants gave in-
formed consent for testing before samples were taken,
and the study was approved by the North Wales
Research Ethics Committee. Sample collection was facil-
itated through the Genetic Beta Cell Research Bank (5-
year extension; MREC no. 17/WA/0327). This process
was set up to ensure effective guardianship of samples
obtained during routine clinical diagnostic procedures,
where consent for genetic testing included permission to
store excess samples for research into improvements in
diagnosis, care, and treatment of genetic diabetes.
SAMPLE PROCESSING AND DNA EXTRACTION
Participants had a venous blood draw of 20 mL into
cell-stabilizing blood collection tubes (Streck), and
plasma was separated within 7 days. Plasma was stored
at 80 C before extraction of cfDNA using the
QIAamp Circulating Nucleic Acid Kit (Qiagen), with
replicate extractions from the same plasma sample
pooled for ddPCR analysis.
Fetal genotype was determined postnatally by mo-
lecular genetic analysis of DNA extracted from cord
blood (n¼ 26), saliva (n¼ 9), venous blood (n¼ 1), or
chorionic villus sampling (n¼ 2). Maternal cell contam-
ination in cord blood and chorionic villus sampling was
excluded by microsatellite analysis using a PowerPlex 16
Kit (Promega) with a threshold of <5% maternal
contamination.
VARIANT ASSAY DESIGN AND DDPCR
For detection of pathogenic variants in GCK or
HNF4A, custom hydrolysis probe assays were designed
using online tools available via the websites of Thermo
Fisher Scientific and Bio-Rad Laboratories; primer and
probe sequences are available on request. We initially
attempted design for 34 unique SNVs or 1- or 2-bp
indels in GCK or HNF4A. Two of these, for GCK var-
iants c.1343G>T, p.(Gly448Val) and c.1175G>C,
p.(Arg392Pro), either failed the suppliers’ design and
manufacture processes or yielded assays that were unable
to provide sufficient detection or discrimination of the
target alleles; samples with these variants were excluded
from the cohort. A complete list of the 32 remaining
variants for which working assays were obtained is
shown in Table 1. All assays were carried out using a
Bio-Rad QX200 system with automated droplet genera-
tion, with reactions set up in ddPCR Supermix for
Probes without dUTP (Bio-Rad), according to the man-
ufacturer’s instructions. Assays were initially optimized
by performing a series of reactions across a temperature
gradient using the appropriate maternal genomic DNA
(gDNA) as a heterozygous control and either paternal
gDNA or an unrelated control as a homozygous refer-
ence. Specificity for the appropriate GCK or HNF4A
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variant was then verified by testing heterozygous mater-
nal gDNA samples carrying the appropriate variant. Of
the 32 custom assays used (24 GCK, 8 HNF4A var-
iants), 31 showed the expected 50:50 allelic balance,
and a single assay (GCK NM_000162 c.239G>T; p.
Gly80Val) showed a slight apparent bias for the refer-
ence allele (Supplemental Fig. 1).
For analysis of cfDNA, assays contained 5 lL of
undiluted sample per 20-lL reaction, with up to 16 rep-
licate wells set up as sample volume allowed. Control
reactions were performed using parental gDNA
(duplicate 20-lL reactions containing 20 ng undigested
gDNA per well) and the same number of template-free
control wells as used for cfDNA samples. Raw data were
collected and analyzed using QuantaSoft analysis soft-
ware (Bio-Rad), with data from replicate wells merged
as appropriate.
For pregnancies in which the fetus was known to
be male, fetal fraction in cfDNA samples was deter-
mined by ddPCR using a hydrolysis probe assay specific
for the X-linked or Y-linked genes encoding zinc finger
protein (ZFX or ZFY, respectively) (17). For cases in
Table 1. Details of GCK and HNF4A variants and affected families.
Gene RefSeq transcript cDNA effect Protein effect Assay name Family/families
GCK NM_000162 c.45þ1G>T n/a c.45þ1G>T 19
GCK NM_000162 c.128G>C p.Arg43Pro R43P 7
GCK NM_000162 c.130G>A p.Glu44Ser G44S 10
GCK NM_000162 c.149dup p.His50fs H50fs 26
GCK NM_000162 c.239G>T p.Glu80Val G80V 33
GCK NM_000162 c.370G>A p.Asp124Asn D124N 1
GCK NM_000162 c.449T>C p.Phe150Ser F150S 21
GCK NM_000162 c.476T>A p.Ile159Asn I159N 17
GCK NM_000162 c.478G>A p.Asp160Asn D160N 20
GCK NM_000162 c.499T>C p.Trp167Arg W167R 32
GCK NM_000162 c.523G>A p.Glu175Arg G175R 8
GCK NM_000162 c.540T>G p.Asn180Lys N180K 14
GCK NM_000162 c.556C>T p.Arg186Ter R186X 3, 12, 30
GCK NM_000162 c.645C>A p.Tyr215Ter Y215X 25
GCK NM_000162 c.736G>A p.Glu246Arg G246R 35
GCK NM_000162 c.778T>G p.Phe260Val F260V 4
GCK NM_000162 c.895G>C p.Glu299Arg G299R 28
GCK NM_000162 c.896G>A p.Glu299Asp G299D 2
GCK NM_000162 c.1019þ1G>A n/a c.1019þ1G>A 29
GCK NM_000162 c.1019G>T p.Ser340Ile S340I 34
GCK NM_000162 c.1148C>T p.Ser383Leu S383L 22
GCK NM_000162 c.1156delC p.Leu386fs L386fs 31
GCK NM_000162 c.1340G>A p.Arg447Gln R447Q 15, 24
GCK NM_000162 c.1361C>T p.Ala454Val A454V 16
HNF4A NM_175914 c.194G>A p.Ser65Asn S65N 27
HNF4A NM_175914 c.219del p.Cys74fs C74fs 23
HNF4A NM_175914 c.246G>A p.Val82Val V82V 13
HNF4A NM_175914 c.319þ5G>A n/a c.319þ5G>A 6
HNF4A NM_175914 c.320C>A p.Ala107Asp A107D 5
HNF4A NM_175914 c.322G>A p.Val108Ile V108I 18
HNF4A NM_175914 c.868C>T p.Arg290Cys R290C 11
HNF4A NM_175914 c.932G>A p.Arg311His R311H 9
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which the fetal gender was either female or unknown,
parental gDNA was genotyped using a panel of 24 com-
mon coding variants (18) to identify informative SNVs
(i.e., where parents were opposite homozygotes). For cases
in which no paternal gDNA sample was available, DNA
libraries were prepared for massively parallel sequencing
from 25 ng cfDNA using the ThruPLEX Tag-seq Kit
(Rubicon Genomics) and subjected to targeted sequence
capture using a custom panel designed to capture all
known monogenic diabetes genes (19) and including
probes to capture the same panel of common coding
SNPs described by Pengelly et al. (18). Variants were fil-
tered for those with minor allele abundance in the range
expected for bona fide paternally inherited alleles (1%–
15%), and after confirmation of maternal genotype by
ddPCR, these SNVs were used to determine fetal fraction
in cfDNA samples by ddPCR as above.
STATISTICAL ANALYSIS
A Bayesian Markov chain Monte Carlo (MCMC) analy-
sis was conducted using JAGS (20). The model is speci-
fied in terms of the data-generating process and vague
prior distributions on unobserved parameters, and then
the MCMC process infers posterior distributions on the
unobserved parameters in accordance with the observed
data, the model, and Bayes’s theorem (21). The 2 key
unobserved parameters for each sample are the fetal
genotype and the fetal fraction. Further details are
provided in the online Supplemental Data. Four
MCMC chains were used, with a 1000-iteration adapta-
tion phase, 10 000 iteration burn-in, and 50 000 itera-
tion sampling, for a total of 200 000 sampled iterations
across the chains. Convergence was assessed visually
by use of the trace plots. For each sample, the analysis
produced a single estimate of the probability of fetal
homozygosity and an estimate of the fetal fraction.
Both ddPCR and calculation of probability for
homozygous reference genotype were performed blind
to the known genotype, which was determined at com-
pletion of each pregnancy.
Results
The cfDNA samples were assayed by ddPCR to quan-
tify alleles of the maternal GCK or HNF4A variant and
the informative SNP identified for determination of fe-
tal fraction (Supplemental Table 1). In total, 57 plasma
samples collected during 38 pregnancies were analyzed
for the familial GCK or HNF4A variants. Two samples
were of insufficient volume for fetal fraction determina-
tion, although in both cases at least one other sample
from the same pregnancy was available for testing.
Analysis of ddPCR data showed that at higher values
of fetal fraction, samples clearly segregated into 2 popu-
lations on the basis of fractional abundance of the
reference allele, consistent with the known genotype
(Fig. 1). However, at the lower range of fetal fraction,
there was considerable overlap between data from het-
erozygous and homozygous pregnancies; this prevented
confident prediction of fetal genotype based on simple
inspection of ddPCR data. In some cases, these samples
had a low proportion of fetal DNA (<2%) or low abso-
lute DNA concentration, yielding <10 positive droplets
for the paternal allele in the fetal fraction assay (open
symbols in Fig. 1). Because accurate inference of fetal
genotype is dependent on both fetal fraction and DNA
concentration, we excluded these samples from further
analysis on the basis that they were unlikely to provide a
reliable prediction. Nevertheless, unambiguous assign-
ment of fetal genotype remained difficult for some sam-
ples in the range of fetal fraction 2%–5%. To provide a
quantitative prediction of genotype from ddPCR data,
we developed a custom Bayesian MCMC model to de-
rive probability for fetal homozygosity of the reference
allele for the appropriate GCK or HNF4A variant.
The Bayesian MCMC model incorporated ddPCR
data from both the GCK or HNF4A variant and fetal
fraction assays; probability scores were initially calcu-
lated from the first sample taken during each pregnancy,
where this met our minimum threshold of 2% fetal
fraction and 10 positive droplets for the paternal allele
in the fetal fraction assay (n¼ 33). In most cases (30/
33), probability scores lay very close to upper or lower
limits, indicating a high likelihood of fetal homozygosity
or heterozygosity, respectively, and in these 30 samples,
there was 100% concordance between the probability
score and the actual genotype (Fig. 2, filled symbols;
sample nomenclature is shown as [family number]-
[pregnancy number]-[weeks gestation]). Mean fetal frac-
tion in these samples was 10.6% (range, 2.5%–26.1%),
with a mean gestational age of 25 weeks (range, 9–
36 weeks). However, samples yielding intermediate
probability scores (Fig. 2, open symbols) raised the
potential for false-positive (family 8, pregnancy 2) or
false-negative (family 5) calls for fetal inheritance of the
variant. Two of these samples, 5-1-11 and 8-2-20, had a
fetal fraction close to our lower threshold of 2%,
whereas 17-1-20 had a low amplifiable DNA concentra-
tion and yielded only 20 positive droplets for the pater-
nal allele in the fetal fraction assay. Inspection of the
raw ddPCR data (Fig. 1) showed it was not possible to
confidently call genotype from these samples within the
95% CIs generated by QuantaSoft, and in that respect
the intermediate probability scores derived from the
Bayesian analysis accurately reflected the raw data. We
attributed the uncertainty in the raw data simply to the
variable and stochastic nature of sampling error, which
would have increased impact at the lower end of the
ranges of fetal fraction and DNA concentration. In these
3 cases of samples with intermediate probability scores
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(0.05p 0.95), we carried out “follow-up” testing of a
second sample from the same pregnancy. In all 3 cases,
these samples yielded high probability scores concordant
with the actual genotype. Furthermore, testing of all avail-
able samples from all pregnancies showed that for samples
generating probability scores of 0.05 or 0.95, there
was complete concordance of predicted genotype both be-
tween samples from the same pregnancy and with the ac-
tual genotype (Supplemental Table 2). This result
indicated that these thresholds were likely appropriate for
the elimination of false calls for fetal homo- or heterozy-
gosity. Using these thresholds, application of the Bayesian
model to ddPCR data generated genotype calls in 33 of
38 pregnancies from our initial cohort (Fig. 3), with no
false positives or false negatives, representing 86.8% clini-
cal sensitivity and 100% clinical specificity.
Discussion
We developed a probabilistic model for ddPCR analysis
of cfDNA samples for prediction of fetal genotype. This
noninvasive assay measures the allelic balance of a path-
ogenic variant in combination with fetal fraction. Using
conservative thresholds, whereby genotype is called only
when the probability of a homozygous fetal genotype is
0.95 or 0.05, the predicted results were 100%
concordant with postnatal genotyping in a retrospective
cohort of 33 of 38 pregnancies. In 3 of these, a high-
probability call was made using a follow-up sample from
the same pregnancy. In the 5 pregnancies for which we
were unable to make a genotype call, this was due to
samples failing our minimum thresholds for fetal frac-
tion or numbers of positive droplets, and no further
samples were available for testing. However, in the clini-
cal setting, we would anticipate that the diagnostic
yield could be improved because, in the case of a failed
test from the first sample, a follow-up sample could be
obtained and tested within an appropriate timescale to
inform management of the pregnancy.
Management of pregnancies in women at risk of
fetal macrosomia due to monogenic diabetes variants
currently requires serial ultrasound scanning from 26
Fig. 1. Allele abundance and fetal fraction in cfDNA. Fractional abundance of the GCK or HNF4A reference allele for each variant
(y-axis) is plotted against fetal fraction (x-axis) for 55 cfDNA samples from 38 pregnancies. Data points from pregnancies in
which fetal genotype was homozygous reference or heterozygous are shown as circles or squares, respectively; in both cases,
filled symbols show samples meeting quality thresholds for ddPCR analysis, whereas open symbols show samples with fetal
fraction <2% (threshold indicated by vertical broken line) or with <10 positive droplets for the paternal allele in fetal fraction
assays (7 and 1 samples, respectively). Error bars show 95% Poisson confidence intervals, as calculated by QuantaSoft software.
The horizontal broken line indicates 50% fractional abundance, along which samples derived from pregnancies with heterozy-
gous fetal genotype would be expected to lie.
Noninvasive Fetal Genotyping of Maternal Variants
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weeks’ gestation to identify fetal overgrowth, with the
option of preterm delivery or elective cesarean or the
induction of labor at 38 weeks’ gestation. Our model
allowed us to accurately call fetal genotype in samples
taken as early as 9 weeks’ gestation; however, although
there was a general trend within the cohort of increasing
fetal fraction with gestational age (as expected), there
was considerable variation between samples at any given
time point (Supplemental Fig. 2). Therefore, during an
ongoing pregnancy, it would be more practical to un-
dertake NIPT during the second or early third trimester,
when cffDNA would be more abundant in the maternal
circulation. In our cohort, we were able to make high
confidence calls for 37 of 40 (92.5%) plasma samples
collected at 20 weeks’ gestation if they met our thresh-
olds for fetal fraction and DNA concentration. The
time required for design, synthesis, and optimization of
custom hydrolysis probes is typically 3–4 weeks, provid-
ing adequate time between referral and testing in the
second or third trimester, given that the maternal vari-
ant will be known at the time of referral. Moreover,
once the appropriate ddPCR assays have been set up,
the turnaround time for testing is only 2–3 days, allow-
ing adequate time for resampling and follow-up testing
if required.
Although other studies have also made use of
ddPCR for NIPT, our method offers the potential
advantage of providing an objective, probabilistic score
for fetal genotype based on both allelic balance of the
variant in question and the fetal fraction. As such, we
were able make high-confidence calls in samples with fe-
tal fraction as low as 2.5%. By comparison, the lowest
fetal fraction supporting genotyping of X-linked and
Fig. 2. Probability of fetal genotype for homozygosity. Probability scores for fetal homozygosity, derived from the custom
Bayesian model, shown for 33 pregnancies in which at least 1 sample passed ddPCR quality thresholds. Pregnancies in which
fetal genotype was homozygous reference or heterozygous are shown as circles or squares, respectively; in both cases, filled
symbols show samples in which the model determined fetal genotype with  95% probability (i.e. P 0.95 for homozygous
reference, P 0.05 for heterozygosity; n¼ 30), whereas open symbols show samples with intermediate probability scores
(n¼ 3).
Fig. 3. Summary of workflow and results.
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recessive disorders in a ddPCR-based assay was 3.6%
(11), whereas the lowest fetal fraction reported in
diagnoses made following exome sequencing of
cfDNA was 4.9% (8). This finding shows that applica-
tion of our statistical method has the potential to
improve the clinical sensitivity of NIPT without
compromising specificity and thus may have implica-
tions for noninvasive genotyping of maternal variants
in other conditions.
A potential limitation of our approach is the meth-
odology used for detection of the pathogenic variant.
Our study cohort included patients with either SNVs or
small indels (1–2 bp), which allowed design of probe-
based hydrolysis assays in which both alleles could be
detected simultaneously. Such variants comprise the ma-
jority of reported GCK and HNF4A pathogenic or likely
pathogenic variants, but larger indels (3 bp) and copy
number variants account for approximately 9.7% or
8.3% of GCK or HNF4A variants, respectively, in the
Human Gene Mutation Database (22). In such cases, it
should be possible to use a modified ddPCR assay to
measure copy number of the reference allele rather than
the balance of both reference and variant alleles; indeed,
we have used this approach for analysis of cfDNA sam-
ples from pregnancies in which the mothers carried dele-
tions of either 13 bp or approximately 36.5 kb in GCK
(Supplemental Fig. 3). Nevertheless, although copy
number variants and larger indels also appear amenable
to testing by ddPCR—albeit with a requirement for
modified data analysis compared with that used for our
main cohort—there may be some variants for which a
suitable assay cannot be designed or for which probes
do not exhibit adequate specificity for the reference and
variant alleles. We were unable to obtain working assays
for 2 variants, likely because of the high GC content
around the position of the variant. For this reason, we
continue to explore other methods for the accurate and
precise quantitation of alleles in cfDNA. These include
massively parallel sequencing following targeted capture,
which has been reported to be successful in prenatal di-
agnosis of X-linked diseases (23) and multiple mono-
genic disorders (8). Notwithstanding such alternatives,
we regard ddPCR as the default method of choice for
the detection and quantitation of known variants at the
current time, as we were able to perform accurate geno-
typing for 94.1% (32/34) of all SNVs and small indels
in our original cohort, while successful genotyping of 2
larger indels provides scope for wider applicability of the
ddPCR-based analysis.
In summary, we describe the development of a
rapid, sensitive, and precise method for the prediction
of fetal genotype in maternally inherited monogenic dis-
eases. This approach has potential applicability to the
management of macrosomia risk in monogenic diabetes
pregnancies and offers considerable improvement in
prediction of fetal genotype compared with the current
ultrasound scanning approach, which has accuracy of
only 56%–72%. Further work is required to investigate
the wider applicability of the ddPCR assay for the early
detection of fetal genotype and the management of
clinical care both during and after pregnancy in other
monogenic diseases.
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